Some of the most common or potential side effects include: Nausea Constipation Vomiting Diarrhea Abdominal Pain Headache Indigestion Injection site reactions Dizziness Back pain Increased Lipase or Amylase Altered taste Nasopharyngitis (common cold) Passing Gas Bloating Belching Gastroenteritis Decreased appetite Fatigue Gastroesophageal reflux disease Low blood sugar (hypoglycemia) in those with Type 2 diabetes Upset stomach These symptoms often subside as your body adjusts to the medications
others are approved for type 2 diabetes and may be used off-label for weight management under clinician supervision
On average, completers achieved 11.5% weight loss vs 7.3% for placebo at 56 weeks 1,3,5 ITT-LOCF: 8.1% weight loss for CONTRAVE and 4.9% for placebo 1 Completers lost an average of 25 lb vs 16 lb for placebo at 56 weeks 5 ITT-LOCF: ~18 lb for CONTRAVE and ~11 lb for placebo 1 There was an average decrease of 4.4 inches in waist circumference for completers vs 3.0 inches for placebo 6 ITT-LOCF: Decrease of 3.9 inches for CONTRAVE and 2.7 inches for placebo 1 In another randomized controlled trial (COR-I) with similar average baseline parameters to those for COR-BMOD, endpoint results over 56 weeks in completers/ITT groups for patients taking CONTRAVE (n=296/538) vs placebo (n=290/536), respectively, were mean weight change from baseline (8.1%/5.4% decrease vs 1.8%/1.3%), patients achieving 5% weight loss (62%/42% vs 23%/17%), and mean change in waist circumference (2.7-inch/2.4-inch decrease vs 1.0 inch/1.0 inch)
Notably, NPY plays a significant role in various physiological processes, including the regulation of appetite, stress responses, and control of blood pressure
The drug is only approved for weight loss in people with a body mass index over 30, or over 25 with another condition like type 2 diabetes or high cholesterol
